Picture of Ayala Pharmaceuticals logo

ADXS Ayala Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Advaxis Inc expected to post a loss of 4 cents a share - Earnings Preview

* Advaxis Inc  ADXS.OQ   ADXS.O  is expected to show a no change
in quarterly revenue when it reports results on September 9
(estimated). 
​* Refinitiv's mean analyst estimate for Advaxis Inc is for a
loss of 4 cents per share. For the same quarter last year, the
company reported a loss of 9 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Advaxis Inc is
$2.25​, about 78.9% above​ its last closing price of $0.47. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Apr. 30 2021  -0.05       -0.05      -0.04     Beat    20
                                                        ​
 Jul. 31 2020              -0.15      -0.09     Beat    40
 Apr.          -0.15​      -0.15      -0.10     Beat    33.3​
 30​ 2020​                                              
 Jan. 31 2020              -0.19      -0.15     Beat    21.1​
 Oct. 31 2019  -0.31       -0.31      -0.15     Beat    51.6
 Jul. 31 2019  -1.34       -1.32      -1.00     Beat    24.2
 This summary was machine generated September 9 at 02:51 GMT. 
All figures in US dollars unless otherwise stated

Recent news on Ayala Pharmaceuticals

See all news